AstraZeneca (AZ) has reported Q1 2026 total revenue of USD 15.3 billion, an 8% year-on-year increase. Product sales grew 8% to USD 15.2 billion. Oncology was the primary growth driver, with the segment's revenue increasing 16% to USD 6.8 billion. Key performers included Imfinzi (durvalumab), up 30% to USD 1.7 billion, and Enhertu (trastuzumab deruxtecan), up 34% to USD 831 million. The TROP2 ADC drug Datroway (datopotamab deruxtecan) saw revenue surge over 1000% to USD 43 million, reaching a total alliance revenue of USD 102 million with Daiichi Sankyo. Meanwhile, sales in China grew 2% to USD 1.9 billion.

The company highlighted 14 major regulatory approvals and four positive Phase III trial readouts in the quarter, including positive data for the IL-33 inhibitor tozorakimab in chronic obstructive pulmonary disease (COPD) and for Ultomiris (ravulizumab) in IgA nephropathy (IgAN). For the full year 2026, AZ expects total revenue to grow in the mid-to-high single-digit percentage range.

According to PharmCube's NextBiopharm® database, tozorakimab previously failed a number of Phase II trials for different immunology indications, including COPD, where it showed positive efficacy signals only in a subgroup of patients with a high risk of exacerbations. Click here to request a free trial for NextBiopharm®.